The effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) remains controversial. Our analysis showed that EGFR-TKIs plus anti-VEGF/VEGFR therapy significantly prolong PFS in the second-line treatment of NSCLC patients. EGFR mutation is a promising indication of this combination treatment.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iUKqHk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018 Apr;287(1):11-28 Authors: Haller S, Vernooij MW, Kuij...
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Excerpt from Common Culture: Reading and Writing About American Popular Culture. Ed. Michael Petracca, Madeleine Sorapure. Upper Saddle Rive...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου